SG Americas Securities
LCTX icon

SG Americas Securities’s Lineage Cell Therapeutics LCTX Stock Holding History

SG Americas Securities’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,789
Closed -$25K – 3481
2025
Q4 		$25K Buy
+14,789
New +$25.6K ﹤0.01% 3441
2025
Q3 		– Sell
-13,522
Closed -$12K – 3478
2025
Q2 		$12K Sell
13,522
-49,637
-79% -$29.4K ﹤0.01% 2852
2025
Q1 		$29K Sell
63,159
-5,814
-8% -$3.41K ﹤0.01% 3341
2024
Q4 		$35K Buy
68,973
+18,053
+35% +$13.3K ﹤0.01% 2966
2024
Q3 		$46K Buy
+50,920
New +$47.2K ﹤0.01% 3260
2024
Q1 		– Sell
-30,889
Closed -$34K – 3218
2023
Q4 		$34K Buy
30,889
+11,779
+62% +$12.9K ﹤0.01% 2977
2023
Q3 		$23K Buy
+19,110
New +$26K ﹤0.01% 3035
2022
Q2 		– Sell
-12,935
Closed -$20K – 3508
2022
Q1 		$20K Sell
12,935
-18,607
-59% -$28.9K ﹤0.01% 2884
2021
Q4 		$77K Sell
31,542
-44,238
-58% -$104K ﹤0.01% 3133
2021
Q3 		$191K Buy
+75,780
New +$194K ﹤0.01% 3263
2021
Q1 		– Sell
-13,053
Closed -$23K – 3415
2020
Q4 		$23K Buy
+13,053
New +$18.3K ﹤0.01% 3198
2020
Q2 		– Sell
-72,784
Closed -$60K – 3777
2020
Q1 		$60K Buy
72,784
+50,733
+230% +$50.5K ﹤0.01% 3144
2019
Q4 		$20K Buy
+22,051
New +$18.4K ﹤0.01% 3146
2019
Q2 		– Sell
-14,574
Closed -$19K – 3274
2019
Q1 		$19K Buy
+14,574
New +$18.1K ﹤0.01% 3271
2018
Q2 		– Sell
-11,555
Closed -$27K – 3452
2018
Q1 		$27K Sell
11,555
-59,655
-84% -$140K ﹤0.01% 3136
2017
Q4 		$134K Buy
71,210
+57,036
+402% +$125K ﹤0.01% 2697
2017
Q3 		$35K Buy
+14,174
New +$35.1K ﹤0.01% 3366
2016
Q2 		– Sell
-13,179
Closed -$33K – 2820
2016
Q1 		$33K Buy
+13,179
New +$29.4K ﹤0.01% 2798

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SG Americas Securities's LCTX Position: Q1 2026 in Review

SG Americas Securities sold out of Lineage Cell Therapeutics (LCTX) in Q1 2026, closing a stake of 14,789 shares — an estimated $25K sold.

SG Americas Securities first reported a position in LCTX in Q1 2016 and held it in 18 quarters. The position peaked at $191K in Q3 2021. 130 funds tracked by Wall St. Rank hold LCTX as of Q1 2026.

  • SG Americas Securities reported no remaining Lineage Cell Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SG Americas Securities sold 14,789 Lineage Cell Therapeutics shares in Q1 2026, an estimated $25K.
  • SG Americas Securities first reported a position in Lineage Cell Therapeutics in Q1 2016 and held it in 18 quarters.
  • SG Americas Securities's Lineage Cell Therapeutics position peaked at $191K in Q3 2021.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.